World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 8 August 2016
Main ID:  NCT02574962
Date of registration: 30/08/2015
Prospective Registration: Yes
Primary sponsor: Mamatha Pasnoor, MD
Public title: Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
Scientific title: Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
Date of first enrolment: August 2015
Target sample size: 0
Recruitment status: Withdrawn
URL:  https://clinicaltrials.gov/show/NCT02574962
Study type:  Interventional
Study design:  Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Mamatha Pasnoor, MD
Address: 
Telephone:
Email:
Affiliation:  University of Kansas Medical Center
Key inclusion & exclusion criteria

Inclusion Criteria:

- CIDP diagnosed according to the European Federation of Neurological
Societies/Peripheral Nerve Society (EFNS/PNS) criteria 2010

- Age > 18 years

- Able to give written informed consent

- Patient's signs and symptoms should not be better explained by another disease
process

- Patients can be on prednisone as long as there has been no dose change for 4 weeks
from baseline

- Patients can be on following drugs as long as there has been no change for 60 days
from baseline visit including azathioprine, cyclosporine, cyclophosphamide,
mycophenolate mofetil, intravenous immunoglobulin (IVIg) or other immunosuppressive
drugs

- INCAT score greater than or equal to 2

Exclusion Criteria:

- Presence of any other causes of polyneuropathy or multifocal motor neuropathy, which
in the opinion of the investigator is the major contributor to the numbness and
weakness.

- Other neurologic or orthopedic condition causing weakness

- Treatment with plasma exchange (PLEX) within the last 30 days from baseline

- Participation in another trial within the last 30 days from baseline or two ½ life of
the drug being studied.

- Latent tuberculosis or active infection

- Contraindication per Acthar® Gel prescribing information scleroderma, osteoporosis,
systemic fungal infections, ocular herpes simplex, recent surgery, history or
presence of peptic ulcer, congestive heart failure, uncontrolled hypertension,
primary adrenocortical insufficiency, or adrenal cortical hyperfunction.

- History of prior sensitivity to Acthar® Gel or other porcine products

- Previous or present Infection with hepatitis C and hepatitis B

- Pregnancy or nursing mothers.

- Female subjects of childbearing potential either not using, or not willing to use, a
medically reliable method of contraception for the entire duration of the study, or
not sexually abstinent for the entire duration of the study, or not surgically
sterile.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Chronic Inflammatory Demyelinating Polyneuropathy
Intervention(s)
Drug: H.P. Acthar® Gel
Primary Outcome(s)
Number of Participants With Treatment-Related Adverse Events [Time Frame: 28 Weeks]
Secondary Outcome(s)
Efficacy of study drug [Time Frame: Change from Baseline to 28 Weeks]
Secondary ID(s)
STUDY00002770
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Mallinckrodt
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history